Targeting DNA methylation

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 3938-3946

  Issa, Jean Pierre J ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CARBOPLATIN; DNA; EPIGALLOCATECHIN GALLATE; FLUCYTOSINE DEOXYRIBOSIDE; HYDRALAZINE; INTERLEUKIN 2; PROCAINAMIDE; RETINOIC ACID; S 110; UNCLASSIFIED DRUG; VALPROIC ACID; ZEBULARINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE; CONTINUOUS INFUSION; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; KIDNEY TUMOR; LEUKEMIA; MELANOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; HUMANS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS;

EID: 67449147110     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2783     Document Type: Review

References (60)

1. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447:425-432 PubMed doi:10.1038/nature05918.
2. Toyota M, Issa JP. Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 2005;32:521-530 PubMed doi:10.1053/j.seminoncol.2005.07.003. (Pubitemid 41396429)
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-799 PubMed doi:10.1038/nm1087. (Pubitemid 39070849)
4. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70. PubMed doi:10.1016/S0092-8674(00)81333-81341 (Pubitemid 26358996)
5. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-1113 PubMed doi:10.1126/science.1145720. (Pubitemid 350134889)
6. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008;456:66-72. PubMed doi:10.1038/nature07485.
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-692 PubMed doi:10.1016/j.cell.2007.01.029. (Pubitemid 46273572)
8. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21. PubMed doi:10.1101/gad.947102. (Pubitemid 34049633)
9. Gazin C, Wajapeyee N, Gobeil S, Virbasius CM, Green MR. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007;449:1073-1077 PubMed doi:10.1038/nature06251. (Pubitemid 350014604)
10. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009;15:3927-3937
11. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006;5:37-50. PubMed doi:10.1038/nrd1930.
12. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007;13:1634-7. PubMed doi:10.1158/1078-0432.CCR-06-2076.
13. Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science 2001;293:1089-1093 PubMed doi:10.1126/science.1063443. (Pubitemid 32758081)
14. Rideout WM III, Eggan K, Jaenisch R. Nuclear cloning and epigenetic reprogramming of the genome. Science 2001;293:1093-1098 PubMed doi:10.1126/science.1063206. (Pubitemid 32758082)
15. Hochedlinger K, Blelloch R, Brennan C, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004;18:1875-1885 PubMed doi:10.1101/gad.1213504. (Pubitemid 39025097)
16. Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979;17:771-9. PubMed doi:10.1016/0092-8674(79)90317-90319 (Pubitemid 9252286)
17. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85-93. PubMed doi:10.1016/0092-8674(80)90237-90238 (Pubitemid 10117303)
18. Beumer JH, Parise RA, Newman EM, et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 2008;62:363-8. PubMed doi :10.1007/s00280-007-0603-608 (Pubitemid 351692084)
19. Chuang JC, Yoo CB, Kwan JM, et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 2005;4:1515-20. PubMed doi:10.1158/1535-7163.MCT-05-0172. (Pubitemid 41556433)
20. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006;66:2794-800. PubMed doi:10.1158/0008-5472.CAN-05-2821.
21. Issa JP, Vertino PM, Wu J, et al. Increased cytosine DNA- methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993;85:1235-1240 PubMed doi:10.1093/jnci/85.15.1235. (Pubitemid 23223530)
22. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res 2000;28:2108-2113 PubMed doi:10.1093/nar/28.10.2108.
23. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-556 PubMed doi:10.1038/416552a. (Pubitemid 34288859)
24. Klisovic RB, Stock W, Cataland S, et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res 2008;14:2444-9. PubMed doi:10.1158/1078-0432.CCR-07-1320. (Pubitemid 351551079)
25. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994;91:11797-11801 PubMed doi:10.1073/pnas.91.25.11797. (Pubitemid 24985095)
26. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 2008;113:659-667
27. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435-443 PubMed doi:10.1016/j.ccr.2006.04. 020. (Pubitemid 43832188)
28. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134:573-586 PubMed. (Pubitemid 32245319)
29. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 2009;113:659-667
30. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440 PubMed doi:10.1200/JCO.2002.04.117. (Pubitemid 34525728)
31. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000;18:956-962 PubMed. (Pubitemid 30123770)
32. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (Decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40. PubMed doi:10.1182/blood-2003-03-0687. (Pubitemid 38268953)
33. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens inthe treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232
34. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803
35. Wijermans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with Intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and German MDS study groups. Blood (ASH Annual Meeting Abstracts) [abstr. 26] 2008;112.
36. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133-1137 (Pubitemid 46435392)
37. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7. PubMed doi:10.1182/blood-2006-05-021162. (Pubitemid 46053042)
38. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 2008;111:2382-4. PubMed doi:10.1182/blood-2007-07-103960.
39. List AF, Vardiman J, Issa JP, Dewitte TM. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004;297-317. PubMed.
40. Oki Y, Aoki E, Issa JP. Decitabine-bedside to bench. Crit Rev Oncol Hematol 2007;61:140-152 PubMed doi:10.1016/j.critrevonc.2006.07.010. (Pubitemid 46073782)
41. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308 (Pubitemid 47523148)
42. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006;66:5495-503. PubMed doi:10.1158/0008-5472.CAN-05-2385. (Pubitemid 43844978)
43. Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002;100: 2957-2964 PubMed doi :10.1182/blood.V100.8.2957.
44. Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66:6361-9. PubMed doi:10.1158/0008-5472.CAN-06-0080.
45. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-3891 PubMed doi:10.1200/JCO.2006.09.4169. (Pubitemid 47477265)
46. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-3956 PubMed doi:10.1200/JCO.2005.11.981. (Pubitemid 46218698)
47. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S. A pilot pharmacokinetic study of oral azacitidine. Leukemia 2008;22:1680-1684 PubMed doi:10.1038/leu.2008.145.
48. Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2″-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007;67:6400-8. PubMed doi:10.1158/0008-5472.CAN-07-0251. (Pubitemid 47037524)
49. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 2009;113:659-667
50. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer. Nat Genet 1999;21:103-107 PubMed doi:10.1038/5047. (Pubitemid 29036293)
51. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-3977
52. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705. PubMed doi:10.1016/j.cell.2007.02.005. (Pubitemid 46273577)
53. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008;40:741-750 PubMed doi:10.1038/ng.159. (Pubitemid 351748874)
54. Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008;454:49-55. PubMed doi:10.1038/nature07056. (Pubitemid 351931978)
55. Braiteh F, Soriano AO, Garcia-Manero G, et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patientswith advanced cancers. Clin Cancer Res 2008;14:6296-301. PubMed doi:10.1158/1078- 0432.CCR-08-1247.
56. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84:9-17. PubMed doi:10.1007/s00277-005-0012-21 (Pubitemid 44419734)
57. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-1803 PubMed doi:10.1002/cncr.21792.
58. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9. PubMed doi:10.1182/blood-2006-03- 009142. (Pubitemid 44776863)
59. Gollob JA, Sciambi CJ, Peterson BL, et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006;12:4619-27. PubMed doi:10.1158/1078-0432.CCR-06-0883. (Pubitemid 44297813)
60. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25:4603-4609 PubMed doi:10.1200/JCO.2007.10.8688. (Pubitemid 350035319)